Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification.

Crona J, Taïeb D, Pacak K.

Endocr Rev. 2017 Dec 1;38(6):489-515. doi: 10.1210/er.2017-00062.

PMID:
28938417
2.

New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma.

Taïeb D, Pacak K.

Trends Endocrinol Metab. 2017 Nov;28(11):807-817. doi: 10.1016/j.tem.2017.08.001. Epub 2017 Aug 31. Review.

PMID:
28867159
3.

Functional Imaging Signature of Patients Presenting with Polycythemia/Paraganglioma Syndromes.

Janssen I, Chen CC, Zhuang Z, Millo CM, Wolf KI, Ling A, Lin FI, Adams KT, Herscovitch P, Feelders RA, Fojo AT, Taieb D, Kebebew E, Pacak K.

J Nucl Med. 2017 Aug;58(8):1236-1242. doi: 10.2967/jnumed.116.187690. Epub 2017 Mar 23.

4.

Emerging role of dopamine in neovascularization of pheochromocytoma and paraganglioma.

Osinga TE, Links TP, Dullaart RPF, Pacak K, van der Horst-Schrivers ANA, Kerstens MN, Kema IP.

FASEB J. 2017 Jun;31(6):2226-2240. doi: 10.1096/fj.201601131R. Epub 2017 Mar 6. Review.

PMID:
28264974
5.

Molecular markers of paragangliomas/pheochromocytomas.

Zhikrivetskaya SO, Snezhkina AV, Zaretsky AR, Alekseev BY, Pokrovsky AV, Golovyuk AL, Melnikova NV, Stepanov OA, Kalinin DV, Moskalev AA, Krasnov GS, Dmitriev AA, Kudryavtseva AV.

Oncotarget. 2017 Apr 11;8(15):25756-25782. doi: 10.18632/oncotarget.15201. Review.

6.

PHD2: from hypoxia regulation to disease progression.

Meneses AM, Wielockx B.

Hypoxia (Auckl). 2016 Apr 11;4:53-67. eCollection 2016. Review.

7.

Therapeutic inhibition of prolyl hydroxylase domain-containing enzymes in surgery: putative applications and challenges.

Harnoss JM, Strowitzki MJ, Radhakrishnan P, Platzer LK, Harnoss JC, Hank T, Cai J, Ulrich A, Schneider M.

Hypoxia (Auckl). 2015 Jan 30;3:1-14. eCollection 2015. Review.

8.

The role of PHD2 mutations in the pathogenesis of erythrocytosis.

Gardie B, Percy MJ, Hoogewijs D, Chowdhury R, Bento C, Arsenault PR, Richard S, Almeida H, Ewing J, Lambert F, McMullin MF, Schofield CJ, Lee FS.

Hypoxia (Auckl). 2014 Jul 1;2:71-90. eCollection 2014. Review.

9.

Identification of non-coding genetic variants in samples from hypoxemic respiratory disease patients that affect the transcriptional response to hypoxia.

Roche O, Deguiz ML, Tiana M, Galiana-Ribote C, Martinez-Alcazar D, Rey-Serra C, Ranz-Ribeiro B, Casitas R, Galera R, Fernández-Navarro I, Sánchez-Cuéllar S, Bernard V, Ancochea J, Wasserman WW, García-Rio F, Jimenez B, Del Peso L.

Nucleic Acids Res. 2016 Nov 2;44(19):9315-9330. Epub 2016 Sep 12.

10.

Clinical iron deficiency disturbs normal human responses to hypoxia.

Frise MC, Cheng HY, Nickol AH, Curtis MK, Pollard KA, Roberts DJ, Ratcliffe PJ, Dorrington KL, Robbins PA.

J Clin Invest. 2016 Jun 1;126(6):2139-50. doi: 10.1172/JCI85715. Epub 2016 May 3.

11.

Erythrocytosis due to PHD2 Mutations: A Review of Clinical Presentation, Diagnosis, and Genetics.

Wilson R, Syed N, Shah P.

Case Rep Hematol. 2016;2016:6373706. doi: 10.1155/2016/6373706. Epub 2016 Feb 29.

12.

EGLN1 Inhibition and Rerouting of α-Ketoglutarate Suffice for Remote Ischemic Protection.

Olenchock BA, Moslehi J, Baik AH, Davidson SM, Williams J, Gibson WJ, Chakraborty AA, Pierce KA, Miller CM, Hanse EA, Kelekar A, Sullivan LB, Wagers AJ, Clish CB, Vander Heiden MG, Kaelin WG Jr.

Cell. 2016 Feb 25;164(5):884-95. doi: 10.1016/j.cell.2016.02.006. Erratum in: Cell. 2016 Apr 7;165(2):497.

13.
14.

Bioinformatic Challenges in Clinical Diagnostic Application of Targeted Next Generation Sequencing: Experience from Pheochromocytoma.

Crona J, Ljungström V, Welin S, Walz MK, Hellman P, Björklund P.

PLoS One. 2015 Jul 31;10(7):e0133210. doi: 10.1371/journal.pone.0133210. eCollection 2015.

15.

Whole-exome sequencing defines the mutational landscape of pheochromocytoma and identifies KMT2D as a recurrently mutated gene.

Juhlin CC, Stenman A, Haglund F, Clark VE, Brown TC, Baranoski J, Bilguvar K, Goh G, Welander J, Svahn F, Rubinstein JC, Caramuta S, Yasuno K, Günel M, Bäckdahl M, Gimm O, Söderkvist P, Prasad ML, Korah R, Lifton RP, Carling T.

Genes Chromosomes Cancer. 2015 Sep;54(9):542-54. doi: 10.1002/gcc.22267. Epub 2015 May 29.

16.

Adrenal medullary hyperplasia is a precursor lesion for pheochromocytoma in MEN2 syndrome.

Korpershoek E, Petri BJ, Post E, van Eijck CH, Oldenburg RA, Belt EJ, de Herder WW, de Krijger RR, Dinjens WN.

Neoplasia. 2014 Oct 23;16(10):868-73. doi: 10.1016/j.neo.2014.09.002. eCollection 2014 Oct.

17.

Genetic evidence of a precisely tuned dysregulation in the hypoxia signaling pathway during oncogenesis.

Couvé S, Ladroue C, Laine E, Mahtouk K, Guégan J, Gad S, Le Jeune H, Le Gentil M, Nuel G, Kim WY, Lecomte B, Pagès JC, Collin C, Lasne F, Benusiglio PR, Bressac-de Paillerets B, Feunteun J, Lazar V, Gimenez-Roqueplo AP, Mazure NM, Dessen P, Tchertanov L, Mole DR, Kaelin W, Ratcliffe P, Richard S, Gardie B.

Cancer Res. 2014 Nov 15;74(22):6554-64. doi: 10.1158/0008-5472.CAN-14-1161. Epub 2014 Nov 4.

18.

Human high-altitude adaptation: forward genetics meets the HIF pathway.

Bigham AW, Lee FS.

Genes Dev. 2014 Oct 15;28(20):2189-204. doi: 10.1101/gad.250167.114. Review.

19.

Paragangliomas/Pheochromocytomas: clinically oriented genetic testing.

Martins R, Bugalho MJ.

Int J Endocrinol. 2014;2014:794187. doi: 10.1155/2014/794187. Epub 2014 May 12. Review.

20.

Cell cycle progression in response to oxygen levels.

Ortmann B, Druker J, Rocha S.

Cell Mol Life Sci. 2014 Sep;71(18):3569-82. doi: 10.1007/s00018-014-1645-9. Epub 2014 May 25. Review.

Supplemental Content

Support Center